A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients

Inclusion Criteria:

1. Willing to sign an ICF, able to comprehend and comply with the study procedures.

2. Male or female subjects aged 18 to 65，inclusive.

3. Subjects with a clinical diagnosis of non-segmental vitiligo.

4. Agree to stop all other treatments for vitiligo during the study period.

5. Women of child-bearing potential must have a negative serum pregnancy test within 3days prior to the first study agent administration.

Exclusion Criteria:

1. Diagnosed as other active depigmentation disease.

2. At screening or baseline visits, subject exhibits active inflammatory dermatologicdisease or symptoms that in the opinion of investigators would interfere of vitiligoevaluation or response to treatment.

3. Uncontrolled thyroid function at screening as determined by the investigator.

4. Use of permanent depigmentation treatment or skin grafts.

5. Use of phototherapy, topical or systemic treatments within certain time frame priorto Day1.

6. Have active bacterial/virus/other pathogens infection or infestation that requiremedical intervention.

7. Have progressive or uncontrolled systemic disease, or other concomitant chronicdisease that the investigators believe unsuitable to participate the study.

8. History of alcohol and drug abuse within one year prior to screening; History ofneurological or mental disorders with diagnosis records, such as severe depression,suicidal tendencies, epilepsy, dementia, etc.

9. Have any other reasons determined by the investigator that the subject is noteligible for the study.